Atwood & Palmer’s Sarepta Therapeutics SRPT Stock Holding History

Atwood & Palmer’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.2K	Hold	1,400	–	–	﹤0.01%	307
2026 Q1	$30.5K	Hold	1,400	–	–	﹤0.01%	283
2025 Q4	$30.1K	Hold	1,400	–	–	﹤0.01%	283
2025 Q3	$27K	Hold	1,400	–	–	﹤0.01%	306
2025 Q2	$23.9K	Hold	1,400	–	–	﹤0.01%	304
2025 Q1	$89.3K	Hold	1,400	–	–	0.01%	188
2024 Q4	$170K	Hold	1,400	–	–	0.01%	152
2024 Q3	$175K	Hold	1,400	–	–	0.01%	154
2024 Q2	$221K	Sell	1,400 -1,600	-53%	-$206K	0.02%	137
2024 Q1	$388K	Sell	3,000 -2,194	-42%	-$269K	0.03%	119
2023 Q4	$501K	Sell	5,194 -5,353	-51%	-$514K	0.04%	106
2023 Q3	$1.28M	Hold	10,547	–	–	0.11%	69
2023 Q2	$1.21M	Buy	+10,547	New	+$1.36M	0.11%	78

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Atwood & Palmer's SRPT Position: Q2 2026 in Review

Atwood & Palmer held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 1,400 shares worth $25.2K. The position accounts for ﹤0.01% of the portfolio, ranked #307.

Atwood & Palmer first reported a position in SRPT in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.28M in Q3 2023. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Atwood & Palmer held 1,400 shares of Sarepta Therapeutics worth $25.2K as of Q2 2026.
Atwood & Palmer left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of Atwood & Palmer's portfolio in Q2 2026, its #307 holding.
Atwood & Palmer first reported a position in Sarepta Therapeutics in Q2 2023 and has held it in 13 quarters since.
Atwood & Palmer's Sarepta Therapeutics position peaked at $1.28M in Q3 2023.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Atwood & Palmer's 13F filing for Q2 2026, filed 8 Jul 2026.